dalteparin has been researched along with beta-alanine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 20 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S | 1 |
| Kwok, CS; Loke, YK | 1 |
| Dahl, OE; Eriksson, BI; Friedman, RJ; Hantel, S; Hermansson, K; Huo, MH; Kurth, AA; Schnee, JM | 1 |
| Ageno, W; Prandoni, P | 1 |
| Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Friedman, RJ | 1 |
| Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N | 1 |
| Migliaccio-Walle, K; Rublee, D; Simon, TA | 1 |
| Espada, NG; González, TC; Merino, RG; Nieto, JA | 1 |
| Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C | 1 |
| Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C | 1 |
| Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C | 1 |
| Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK | 1 |
| Klein, HH | 1 |
| Cohen, AA; Rider, T | 1 |
| Gálity, H; Gombár, C; Horvath, G; Sisák, K; Tóth, K | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
10 review(s) available for dalteparin and beta-alanine
| Article | Year |
|---|---|
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Venous Thromboembolism | 2012 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
4 trial(s) available for dalteparin and beta-alanine
| Article | Year |
|---|---|
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment | 2010 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Survival Analysis; Venous Thromboembolism; Venous Thrombosis | 2011 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Prospective Studies | 2014 |
6 other study(ies) available for dalteparin and beta-alanine
| Article | Year |
|---|---|
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Postoperative Complications; Randomized Controlled Trials as Topic; Venous Thromboembolism; Venous Thrombosis | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Health Care Costs; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism | 2012 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Embolectomy; Embolism; Enoxaparin; Fatal Outcome; Femoral Artery; Humans; International Normalized Ratio; Male; Phenprocoumon; Vertebrobasilar Insufficiency | 2012 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism | 2012 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |